Ozmosi | Fumagillin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Fumagillin

Pronounced as: fyoo-ma-JILL-in

Alternative Names: fumagillin, gw-642444, gw642444, gw 642444
Clinical Status: Active
Latest Update: 2024-04-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Angiogenesis Inhibitor, METAP2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: *

Approval Status: Not Approved

Approved Countries: France

Approved Indications: None

Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Asthma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2017-001532-19

2017-001532-19

P3

Active, not recruiting

Asthma

2021-03-11

50%

2022-03-13

Treatments